The growing uses of medicinal cannabis
Pharmaceutical Technology
MARCH 6, 2024
Demand for medicinal cannabis is increasing globally to treat a range of illnesses and conditions.
Wed.Mar 06, 2024
340 
There’s a Surprisingly Simple Way to Remove Microplastics From Your Drinking Water
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 6, 2024
Tiny fragments of microplastics are making their way deep inside our bodies in concerning quantities, significantly through our food and drink. Scientists have now found a simple and effective means of removing them from water.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
J&J seeks EU approval for new Darzalex multiple myeloma indication
Pharmaceutical Technology
MARCH 6, 2024
J&J submitted a new application to the EMA for the approval of its Darzalex combination therapy for multiple myeloma.
Regenxbio data suggest ‘niche’ in Duchenne gene therapy
Bio Pharma Dive
MARCH 6, 2024
Study results showed early signs of promise in Duchenne patients who are currently ineligible to receive Sarepta’s Elevidys, triggering a stock surge.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Sorrento Therapeutics files patent for stable oral liquid pharmaceutical composition of celecoxib for pain relief
Pharmaceutical Technology
MARCH 6, 2024
Experience rapid pain relief with Sorrento Therapeutics' stable oral liquid pharmaceutical composition of celecoxib. Patent filed for effective pain management within 2 hours.
Gilead bets on ‘trispecifics’ in latest cancer drug deal
Bio Pharma Dive
MARCH 6, 2024
A small partnership with Merus adds to Gilead’s string of cancer dealmaking, which, so far, has not paid off for the large biotech.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Sionna raises another $182M to challenge Vertex in cystic fibrosis
Bio Pharma Dive
MARCH 6, 2024
Incubated by RA Capital and backed by a wide array of investors, the startup is developing drugs that work differently than Vertex’s market-leading medicines.
March 6, 2024: In This Week’s PCT Grand Rounds, Public-Private Partnerships in Health AI
Rethinking Clinical Trials
MARCH 6, 2024
In this Friday’s PCT Grand Rounds, Michael Pencina of Duke University will present “Public-Private Partnerships in the Trustworthy Health AI Ecosystem.” The Grand Rounds session will be held on Friday, March 8, 2024, at 1:00 pm eastern. Pencina is a professor of biostatistics and bioinformatics and the vice dean for data science in the Duke University School of Medicine.
Alumis, taking aim at Bristol Myers, pulls in $259M for TYK2 drug work
Bio Pharma Dive
MARCH 6, 2024
The startup, one of a number of young biotechs coming after Bristol Myers’ Sotyktu, will use the cash to fund a late-stage trial in plaque psoriasis.
Avacta Group files patent for extended circulating serum half-life therapeutic conjugates
Pharmaceutical Technology
MARCH 6, 2024
Discover Avacta Group's groundbreaking patent for therapeutic conjugates with extended half-life, targeting improved efficacy in treating diseases like cancer. Learn more about this innovative approach now!
European VC Invivo readies its latest fund to back new biotechs
Bio Pharma Dive
MARCH 6, 2024
The Barcelona-based firm, which is targeting about €100 million for the new fund, is eyeing investments in AI, synthetic biology, and cell and gene therapy.
Sonrai Analytics and Candel to advance cancer treatment using AI
Pharmaceutical Technology
MARCH 6, 2024
Sonrai Analytics has entered a partnership with Candel to expedite the development of viral immunotherapies for treating cancer.
AstraZeneca pledges £650M in UK investments to boost vaccine capabilities, expand near HQ
Fierce Pharma
MARCH 6, 2024
AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing a big chunk of money into the Big Pharma’s home country. | AstraZeneca CEO Pascal Soriot, who has been critical of the U.K.’s business environment for the life sciences industry, is directing £650 million into the Big Pharma’s home country.
Navigating Mental Wellness: Understanding Neurodiversity and Self-Kindness
Pharma Mirror
MARCH 6, 2024
Presented by BetterHelp. In the mental wellness space, neurodiversity can sometimes be overlooked. Although neurodivergent diagnoses differ from mental health concerns, there are often aspects of the diagnosis that can present mental health challenges for some people. For anyone diagnosed with a condition or disorder, self-esteem challenges can arise.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Why small particles matter: Manufacturing and micro-material contamination
Pharmaceutical Technology
MARCH 6, 2024
To protect patient safety and reduce recall risks, drug manufacturers must reduce particle contamination sources wherever possible.
Researchers aim to ensure future AI healthcare monitoring systems are free of gender bias
Pharma Times
MARCH 6, 2024
The project will train a newly developed AI system on data collected from participating men and women
Akari Therapeutics enters merger deal with Peak Bio
Pharmaceutical Technology
MARCH 6, 2024
Akari Therapeutics has signed an agreement with Peak Bio to merge in an all-stock transaction, creating a diversified pipeline.
Researchers use collected stem cells to grow cell models to advance prenatal medicine
Pharma Times
MARCH 6, 2024
CDH affects one in 5,000 babies born in the UK, impacting the foetus’ development of vital organs
Ono signs licence deal with NEX-I for cancer therapy
Pharmaceutical Technology
MARCH 6, 2024
Ono Pharmaceutical has signed an exclusive licence agreement for the development and marketing of NEX-I’s new cancer therapy, NXI-101.
12 Questions with Jorge Reis-Filho
pharmaphorum
MARCH 6, 2024
Get to know Jorge Reis-Filho, Vice President of Cancer Biomarker Development at AstraZeneca, through this exclusive interview featuring 12 insightful questions. Gain insights into his role, career journey, and the latest advancements in cancer biomarker development.
FDA approves Sandoz’s two denosumab biosimilars
Pharmaceutical Technology
MARCH 6, 2024
The US Food and Drug Administration (FDA) has granted approval for Sandoz’s Wyost and Jubbonti, two biosimilars of denosumab.
Automation of literature search and review
pharmaphorum
MARCH 6, 2024
Looking to automate your literature search and review process in pharmacovigilance? Learn how AI can streamline the detection and analysis of Adverse Events (AE) effectively.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
WHO flags increasing resistance to GSK's HIV med Tivicay in some countries
Fierce Pharma
MARCH 6, 2024
GSK's antiretroviral HIV medicine Tivicay (dolutegravir) has been recommended by the World Health Organization since 2018 as a preferred treatment for the virus. | The World Health Organization (WHO)'s latest HIV Drug Resistance report showed that some patients are developing resistance to Tivicay, which has been recommended as a preferred treatment since 2018.
Grand Rounds March 1, 2024: Effect of an Intensive Food-As-Medicine Program on Health and Health Care Use: Evidence from a Randomized Clinical Trial (Joseph Doyle, PhD)
Rethinking Clinical Trials
MARCH 6, 2024
Speaker Joseph Doyle, PhD Erwin H. Schell Professor of Management and Applied Economics MIT Sloan School of Management Slides Keywords Food-as-Medicine, Randomized Clinical Trial, Diabetes Key Points Diabetes is common and costly. 9% of the U.S. has the condition; it is responsible for 300,000 premature deaths/year and $330 billion in annual healthcare spending.
UK Chancellor trumpets £650m AstraZeneca investment
pharmaphorum
MARCH 6, 2024
A £650 million investment package by AstraZeneca in the UK has been held up by Chancellor Jeremy Hunt as a “vote of confidence” in the country’s life sciences sector. AZ is preparing to invest £450 million at its manufacturing site in Speke, Liverpool, to boost research, development and manufacturing of vaccines, including the construction of a new plant that will be powered by renewable energy, according to a government statement.
GELATIN-Free Medicines: Which Drugs Contain GELATIN?
Drug Patent Watch
MARCH 6, 2024
GELATIN-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Gelatin-Free Medicines on Amazon This guide is designed to provide information for healthcare providers to… The post GELATIN-Free Medicines: Which Drugs Contain GELATIN? appeared first on DrugPatentWatch - Make Better Decisions.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Amid patent fight, Sandoz biosimilars to Amgen bone blockbusters gain FDA nods
Fierce Pharma
MARCH 6, 2024
Two biosimilars to Amgen’s lucrative bone drugs Prolia and Xgeva have clinched approvals at the FDA, though ongoing patent litigation makes launch timing uncertain. | Sandoz has clinched FDA approvals for biosimilars to Amgen’s denosumab. Sandoz’s drugs mark the first approved denosumab biosimilars and treat all indications of the reference products.
NICE no follows Scottish aye for rare disease drug Xenpozyme
pharmaphorum
MARCH 6, 2024
NICE has turned down Sanofi’s Xenpozyme as a treatment for the rare disease acid sphingomyelinase deficiency (ASMD), creating a situation where access to the drug in the UK will depend on a patient’s address.
How Long Will the Current Slowdown in Biotech Investment Last?
Pharmaceutical Commerce
MARCH 6, 2024
In this Pharmaceutical Commerce video interview, Emma Banks, CEO of ramarketing, discusses how the balance between onshoring and outsourcing will evolve, how long will the current slowdown in biotech investment likely last, and what factors might influence its duration.
Sandoz gets first FDA OK for denosumab biosimilars
pharmaphorum
MARCH 6, 2024
Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US market.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content